Why Eli Lilly and Company May Never Get Bought By Valeant Pharmaceuticals International -- Or Anyone Else

Published: Jun 25, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

With its $67 billion market capitalization — about a third that of Pfizer or Merck — Indianapolis-based Eli Lilly often gets mentioned as a buyout candidate. But it will probably never get bought out. The reason, as Sanford C. Bernstein analyst Timothy Anderson explains in a note to investors this morning, is the state law in Indiana.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news